| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
4 companies
Robert J. Spiegel is Director at GERN, with reported holdings spanning 4 companies. Robert J. Spiegel's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $353K at current prices.
Robert J. Spiegel's largest disclosed position is in GERN as Director, worth about $197K. The GERN filings lean toward selling, a net 175,000 shares.
Robert J. Spiegel has 71 Form 4 filings on record from May 2015 to October 2026, across 6 companies: Director at RenovoRx (RNXT), 2023–2026; Director at Geron (GERN), 2015–2026; Director at Bio Green Med Solution (BGMS), 2018–2023, and 3 more.
The 93 reported transactions were 42 stock awards, 32 option or other derivative awards, 7 option exercises and 6 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $33K and 1 sale worth about $1.2M.
The only open-market purchase was 3,000 shares of PDSB at an average $11.00 on October 6, 2015, about $33K.
The only open-market sale was 175,000 shares of GERN at an average $6.85 on September 13, 2018, about $1.2M.